Market Insights Health OTC Pharmaceuticals

Wound Care - LATAM

LATAM

In LATAM, the revenue in the Wound Care market market is projected to reach US$152.90m in 2024.
The market is expected to experience an annual growth rate of -0.88% (CAGR 2024-2028).
When compared globally, the in the United States generates the highest revenue in this market, with US$1,052.00 in 2024.
In terms of per capita figures, each person in LATAM generates revenues of US$0.24 in 2024.
Brazil is experiencing a growing demand for advanced wound care products in the OTC pharmaceuticals market.

Key regions: Australia, Europe, Canada, United States, Japan

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.